DeepMed Research

Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin Degludec/Insulin Aspart

First Posted Date: 2019-08-02

Last Posted Date: 2021-02-21

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1122

Registration Number: NCT04042441

Locations: 🇸🇦
Saudi German Hospital, Jeddah, Saudi Arabia
🇸🇦
My clinic, Jeddah, Saudi Arabia
🇮🇳
Pace Diabetes Center, Bangalore, Karnataka, India

and more 61 locations

A Research Study of How Semaglutide Works in People With Disease Affecting the Heart and/or Blood Vessels and Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo (semaglutide)
Drug: Semaglutide

First Posted Date: 2019-07-25

Last Posted Date: 2025-04-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 101

Registration Number: NCT04032197

Locations: 🇦🇹
Clinical Trials Unit / Center for Medical Research, Graz, Austria
🇸🇪
CTC Clinical Trial Consultants AB, Uppsala, Uppsala, Sweden
🇩🇰
Steno Diabetes Center Copenhagen, Herlev, Denmark

and more 1 locations

A Research Study Comparing a New Medicine Oral Semaglutide to Sitagliptin in People With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Oral semaglutide
Drug: Sitagliptin
Drug: Placebo (sitagliptin)
Drug: Placebo (oral semaglutide)

First Posted Date: 2019-07-12

Last Posted Date: 2024-09-30

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 1441

Registration Number: NCT04017832

Locations: 🇩🇿
Maison des diabétiques El Harrach, Algiers, Algeria
🇩🇿
Department of internal medicine hospital (CHU) of BIRTRARIA, Algiers, Algeria
🇧🇷
Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda., Porto Alegre, Rio Grande Do Sul, Brazil

and more 90 locations

A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese

Phase 1

Completed

Conditions: Healthy Volunteers
Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Oral semaglutide

First Posted Date: 2019-07-12

Last Posted Date: 2024-07-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 32

Registration Number: NCT04016974

Locations: 🇨🇳
Beijing Hospital-phase I, Beijing, Beijing, China

A Research Study to Compare Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

Phase 1

Terminated

Conditions: Overweight
Obesity

Interventions: Drug: Semaglutide (administered by DV3396 pen)
Drug: Semaglutide (administered by PDS290 pen)

First Posted Date: 2019-07-09

Last Posted Date: 2019-10-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 29

Registration Number: NCT04012255

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity

Phase 1

Completed

Conditions: Overweight
Obesity

Interventions: Drug: Placebo (NNC0247-0829)
Drug: NNC0247-0829

First Posted Date: 2019-07-08

Last Posted Date: 2024-01-23

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 103

Registration Number: NCT04010786

Locations: 🇺🇸
ICON Early Phase Services, LLC, San Antonio, Texas, United States

A Study Comparing the Injection Site Pain Experience After the Injection of 2 Different Solutions of Semaglutide With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

Phase 2

Completed

Conditions: Healthy Volunteers Diabetes Mellitus, Type 2
Healthy Volunteers Overweight
Healthy Volunteers Obesity

Interventions: Drug: Semaglutide (administered by DV3396 pen)
Drug: Semaglutide (administered by PDS290 pen)

First Posted Date: 2019-07-05

Last Posted Date: 2020-08-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 103

Registration Number: NCT04007107

Locations: 🇳🇱
Novo Nordisk Investigational Site, Groningen, Netherlands

A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Semaglutide
Drug: Placebo (semaglutide)

First Posted Date: 2019-06-18

Last Posted Date: 2023-02-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 961

Registration Number: NCT03989232

Locations: 🇺🇦
Novo Nordisk Investigational Site, Zhytomyr, Ukraine

A Research Study on How Semaglutide Works in People With Fatty Liver Disease and Liver Damage

Phase 2

Completed

Conditions: Non-alcoholic Steatohepatitis

Interventions: Drug: Placebo (semaglutide)
Drug: Semaglutide

First Posted Date: 2019-06-17

Last Posted Date: 2024-05-29

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 71

Registration Number: NCT03987451

Locations: 🇺🇸
Texas Clinical Research Institute, LLC, Arlington, Texas, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Miami/Schiff Center for Liver Diseases, Miami, Florida, United States

and more 35 locations

An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice

Completed

Conditions: Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2

Interventions: Drug: Faster-acting insulin aspart

First Posted Date: 2019-06-17

Last Posted Date: 2024-06-14

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 42

Registration Number: NCT03987802

Locations: 🇮🇳
Max Super Speciality Hospital, Saket, New Delhi, Delhi, India
🇮🇳
Vijayratna Diagnostic & Scientific Obesity Clinic, Ahmedabad, Gujarat, India
🇮🇳
Life Care Clinic & Research Centre, Bangalore, Karnataka, India

and more 23 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy